By VETTAPHARMA reporter
Global publisher John Wiley & Sons has released a set of comprehensive guidelines aimed at helping authors use artificial intelligence (AI) responsibly in scholarly writing. The guidance addresses growing concerns about the use of generative AI tools, such as language models, in academic research, emphasizing transparency, ethical practice, and human accountability.
The guidelines come as AI technologies increasingly support authors in drafting text, summarizing research, and refining manuscripts. While AI offers efficiency and productivity benefits, Wiley emphasizes that it is a supporting tool rather than a replacement for human expertise. According to the publisher, authors remain fully responsible for the accuracy, originality, and integrity of the content they submit.
Human Oversight Remains Critical
At the core of the guidelines is the principle of human oversight. Authors are instructed to review and validate all AI-generated content, including factual claims, analytical conclusions, and citations. This ensures that the final manuscript reflects the author’s scholarly judgment, rather than the output of an automated system.
“AI tools can assist with initial drafting and organization, but the responsibility for all final content remains with the human author,” Wiley noted in its guidance.
Reviewing AI Tool Terms
The guidelines also stress the importance of understanding the terms and conditions of AI platforms. Some generative AI systems retain rights to the content produced or may use it for model training. Authors are encouraged to select tools that allow them to maintain full control over their manuscripts and ensure that the publisher can legally disseminate the work.
Disclosure and Transparency
Transparency is another key element of Wiley’s framework. Authors are asked to document the use of AI tools in their manuscripts, specifying the tool, its version, the purpose of its use, and how the author verified or edited AI-generated content. This disclosure can be included in the acknowledgments, methods, or a separate declaration, and is intended to foster trust between authors, editors, and readers.
Ethics, Bias, and Privacy Considerations
Wiley’s guidelines also address ethical concerns. AI models may reflect biases in training data, and authors are advised to critically assess outputs to prevent inaccuracies or skewed interpretations. Additionally, AI use should comply with privacy requirements, ensuring that unpublished or sensitive material is not exposed through third-party tools.
AI in Visual Content
The guidelines cover AI-generated visuals as well. Conceptual diagrams and educational illustrations may be generated with AI, but factual or data-driven images require verification by the author to ensure accuracy. Authors must retain intellectual property rights over any AI-assisted visual content.
Looking Ahead
Wiley’s guidelines reflect the publisher’s commitment to maintaining academic integrity in the era of AI-assisted writing. By providing clear expectations for transparency, oversight, and ethical use, the publisher aims to help authors leverage AI effectively while upholding the standards of scholarly communication.
#ScholarlyPublishing #ArtificialIntelligence #ResponsibleAI #AcademicWriting #ResearchIntegrity #PublishingGuidelines #AIEthics #GenerativeAI #ScientificPublishing #ResearchEthics #AcademicResearch #AIinResearch #Wiley #ClinicalTrial #CMPP #ISMPP
Source Credit
Wiley. (2026). AI guidelines: Using AI tools in your writing. John Wiley & Sons. https://www.wiley.com/en-us/publish/book/resources/ai-guidelines/
Disclaimer: The contents published on this platform are intended solely for informational and educational purposes. Reports, summaries, and discussions related to clinical trials are based on publicly available data, press releases, scientific publications, and regulatory disclosures available at the time of reporting. The information provided does not constitute medical advice, diagnosis, treatment recommendations, or endorsement of any drug, therapy, or clinical outcome. Clinical trial data are subject to change as studies progress, and results discussed may be preliminary, incomplete, or not yet peer-reviewed. Readers are strongly encouraged to refer to the original clinical trial records, regulatory filings, and peer-reviewed articles for complete, accurate, and up-to-date information. Healthcare professionals and patients should consult qualified medical professionals and relevant regulatory authorities before making any healthcare or treatment decisions. The platform and its contributors disclaim any liability for actions taken based on the information presented.
